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INTRODUCTION 
 
Over time, breast cancer surgery has evolved from radical surgical 
procedures toward less and less disfiguring procedures and consequently 
improved cosmetic results. 
Immediate breast reconstruction after mastectomy has become ever more 
significant for the body image of women with breast cancer.1 The choice of 
reconstructive treatment depends on the type of mastectomy, the local 
conditions after mastectomy, the clinical history of the patient (metabolic 
diseases, coagulation disorders, smoke, etc.), the patients’ preference and 
the need of postoperative radiotherapy.  
In the past, the limitation of immediate reconstruction with implants was due 
to inappropriate soft-tissue coverage with the following wound dehiscence  
and implant exposure, poor aesthetic outcomes and poor symmetry with high 
and tight breasts.2 Currently, the indications to radical mastectomy are 
decreasing while skin-sparing and nipple-sparing mastectomies are 
growing.3,4,5 This is mainly because mammography screening helps detect 
breast cancer earl,6,7 when it is most easily to treat.  
Thanks to the more conservative mastectomies, the saving of the breast skin 
has been improved allowing the possibility of successful placement of a 
permanent implant at the time of mastectomy.3,8 Therefore, immediate breast 
reconstruction with implants is increasingly required by both the patients and 
the surgeons. This type of surgery gives a less disfiguring cosmetic result, 
reducing the psychological impact of cancer on patients. Oncological 
radicality and aesthetic outcome (satisfying breast shape and symmetry after 
immediate reconstruction) represent a great challenge for the surgeon.  
According to the American Society of Plastic Surgeons, the post-mastectomy 
reconstruction with implants represents the 77% of all reconstructions. The 
remaining 33 % is represented by autologous tissues reconstructions (TRAM, 
Latissimus Dorsi and DIEP).9 Hershman et al. reported that the immediate in-
hospital complication rate was significantly higher in patients who underwent 
autologous flaps when compared to those with implant reconstruction.10 
There are two approaches of immediate reconstruction with implants: two-
stage and one-stage. The traditional one is achieved in two stages with the 
use of tissue expanders and permanent implants. The emerging approach is 
performed in one stage by using permanent implants with or without the use 
of mesh. The immediate use of implants at the time of mastectomy, which 
eliminates the need for a second surgery procedure, has been sparsely 
reported and is not yet accepted as the standard of care. The one-stage 
reconstructive surgery has several advantages, such as lower surgical times 
compared to reconstructions with autologous tissue, reduction of surgical 
procedures and lower costs.11,12 In addition, it should be noted that this 
surgical procedure involves a minor discomfort to the patient in terms of 
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ambulatory accesses for the filling of expander. However, additional cost is 
incurred if breast reconstruction is associated with Acellular Dermal Matrix 
(ADM).13, 14 ADM is frequently used in expander based breast reconstruction 
because facilitates complete implant coverage providing support to the 
inferior-lateral pole of the implant. ADM gives a faster tissue expansion, a 
reduction of post-operative pain and an improvement of the aesthetic 
outcome,15,16 reducing concerns for complications such as rippling and 
malposition.17,18  By contrast the overall early complications can reach a wide 
spectrum.19 
We performed a retrospective study aimed at:  
- analyzing how patient characteristics are associated to surgical 
outcome, after breast reconstruction with implants or tissue expanders; 
- identifying predictive factors which could help patient selection for type 
of reconstruction.  
The study provided first evidence to assess the safety of the direct-to-implant 
reconstruction and the traditional procedure with expander insertion in 
patients affected by primary breast cancer and undergoing total or nipple-
sparing mastectomy and adjuvant therapies. The outcome was the local 
safety in terms of complications and revision surgeries. A statistical analysis 
was performed to analyze the two surgical approaches in terms of type and 
number of local complications and in relation to potential risk factors as 
patient and disease factors, and interferences produced by chemotherapy 
and radiation. 
 
 
Materials and methods 
 
Ethical statement  
This is an observational study that was approved by the institutional Ethics Committee of 
Fondazione IRCCS Istituto Nazionale dei Tumori (registration number: INT 134-2016) and 
complies with the Declaration of Helsinki. The patients gave informed consent to clinical data being 
used for research and being published. The study records were extracted from the institutional 
electronic database and from the clinical charts. Demographics, treatments, and complications were 
recorded prospectively. 
  
Patients and data collection 
 
The series is composed of 262 females undergoing 294 immediate 
reconstructions after mastectomy (32 bilateral cases) at the Istituto Nazionale 
dei Tumori (Milan, Italy) from December 2011 to June 2014. The 
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observational period was from June 2014 to March 2015. All data were 
collected prospectively. No patient was lost to follow-up.  
The mastectomies (166 Total and 128 Nac-sparing) were performed by the 
staff of oncologic surgeons. Axillary sentinel lymph node biopsy or node 
dissection was performed as necessary. Reconstructions were consecutively 
performed by the senior author (E.R.) with immediate placement of 
permanent implant or tissue expander using complete musculofascial 
coverage. Skin-Reducing and radical mastectomies, reconstructions with 
composite pocket (use of ADM and other meshes), the second operation for 
expander- substitution and final aesthetic outcomes were excluded from the 
study, in order to have a homogeneous sample. 
 
Reconstructions were divided into two groups: immediate reconstruction with 
permanent implant (direct-to-implant, DTI) versus expander-based 
reconstruction in two stages (EBR). Sixty-one patients underwent DTI (9 
bilateral cases, for a total of 70 reconstructions). All implants were 410 high-
cohesive models from Allergan Inc. (Irvine, US). 201 patients underwent EBR 
(23 bilateral cases, for a total of 224 reconstructions). The expanders were: 
213 Allergan style 133 and 11 Mentor CPX (Mentor, Santa Barbara, US).  
In order to suggest which factors could show a major or minor propensity to 
risk of complications in the treated patients, it has been considered the 
association of complications with some variables selected on the basis of 
clinical experience. The analyzed variables, potentially associated with the 
outcome, were patient characteristics (age, BMI), risk factors (hypertension, 
smoking, diabetes), characteristics of surgical treatment (type of mastectomy: 
nipple sparing or total mastectomy), prosthetic volume/weight, primary and 
secondary chemotherapy, and radiotherapy.  
 
Complications were divided in two groups based on their severity, major and 
minor depending on the necessity of a revision surgery or not. Major 
complications included necrosis, infection, inflammation, seroma, damage, 
exposure, rupture and lateral dislocation of the implant, which required a new 
surgery with implant replacement. Minor complications mainly included 
inflammation, infection, pain of the wound, abnormal scars and mild lateral 
dislocation of the implant, but they did not require any implant removal. The 
study observed the occurrence of the totality of adverse effects (i.e. major 
and minor complications), because they represent good indicators of 
reliability of the surgical procedure, and analyzed the complications as total 
(minor + major) and major alone, because they were expected to be more 
clinically relevant. 
 
Surgical techniques 
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DTI reconstruction: submuscular pocket with full release of lower insertions 
and deep fascia (harvest of pectoralis major muscle and thin-layer fibers of 
serratus anterior muscle and fascia); full release of the superficial fascial 
system above the inframammary fold (Riggio and Nava);20 implant insertion; 
two drains (submuscular and subcutaneous/axillary). The DTI pocket includes 
a variant of the conventional submuscular pocket that, through a full 
superficial fasciotomy, allows direct extension of the lower pole and insertion 
of larger implants (Riggio et al).21 All breast implants were anatomically 
shaped with high-cohesive silicone gel. 
EBR reconstruction: submuscular pocket (harvest of pectoralis major and 
serratus anterior, with release of lower insertions and deep fascia); expander 
insertion; two drains (submuscular and subcutaneous/axillary). Intraoperative 
fill with saline solution is meanly 35% of the nominal device volume. The 
following fills start 2-3 weeks after surgery, and carry on at every 1- 2 weeks. 
The full expansion can be reached after 2-3 months. This time can be longer 
in patients under chemotherapy. The pocket is totally autologous and 
vascularized, with no interruption of the lower envelope for implants and 
expanders as well. All breast expanders were saline single-lumen and 
integrated-valve tissue expanders. Adjustable/expandable breast implants 
(i.e. Becker-type) were not used. 
 
 
 STATISTICAL ANALYSIS 
 
The main aim of the analysis was to evaluate, in the DTI and in the EBR 
group, the association between complications and the following variables: 
age and prosthetic volume (continuous variables), BMI (<25 Kg/m2; ≥25 
Kg/m2) diabetes (no; yes), hypertension (no; yes), smoking habit (non 
smoker; ex smoker; smoker), type of mastectomy (total; nac sparing), 
radiotherapy (no;yes) and chemotherapy (no therapy; Adjuvant; Neoadjuvant; 
Adjuvant plus neoadjuvant). To such aim, data recorded from 294 
reconstructions were used. The outcomes were: total complications and 
major complications. For the DTI group the analyses were performed only for 
total complications; major complications were not considered because of the 
paucity of observed outcomes (n=3).  
Continuous variables were summarized using median, quartiles (Q1, Q3), 
interquartile range (IQR), minimum and maximum; categorical variables  were 
summarized by frequency counts and percentages. The association among 
outcomes and variables of interest was firstly evaluated through univariate 
logistic models, with complication (total or major) as response variable 
(1=present; 0=absent). For each model, the null hypothesis of no association 
was assessed by the Wald test (two-tailed). In a second step multivariable 
logistic models were estimated for major and total complications in the EBR 
group. The decision of excluding the outcomes of the DTI group was made 
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according to the event per variable (EPV) rule22. The EPV rule is designed to 
avoid estimation bias, by “ruling out” situations in which the number of 
observed events is relatively low. In multivariable models, the variables that 
showed at least a moderate association with the outcome (Odds Ratio>2.5 
for categorical variables; p<0.05 for continuous variables) were included as 
independent variables. Age was included in the model independently on its 
statistical significance, in order to obtain age-adjusted estimates of the 
multivariate Odds Ratios. 
A robust estimation method23 was used to fit the logistic regression models 
(both the univariate and the multivariate ones), due to the unbalanced 
distribution of some covariates (e.g. diabetes), The association between 
outcomes and variables was evaluated through the Wald test (two-
tailed).Results were reported in terms of estimated odds ratios of 
complication, with respective 95% confidence intervals, and the p-values of 
the association tests. For each test, statistical significance was deemed for 
p<0.05. The analyses were performed using the r software version 3.2.424, 
with the logistf  package added.25. 
 
 
RESULTS 
 
DTI group (61 patients) included 70 reconstructions, of which 8 (11.4%) after 
total mastectomy and 62 (88.6%) after nipple-sparing mastectomy (Table 1). 
The median age of patients was 46 years (range: 23-74 years). BMI varied 
from 16.6 to 27.8 with a median of 20.6. Considering the factors of 
cardiovascular risk, none of the patients were diabetic, 4 patients (6.6%) were 
hypertensive, 2 patients (3.3%) were smoker and 12 patients (19.7%) had a 
past smoker. The volume of the implant used varied from 125 ml to 525 ml 
with a median of 370 ml. 
Four patients (6.6%) on 61 underwent radiotherapy. Chemotherapy was 
performed according to adjuvant treatment in 31 patients (50.9%), 
neoadjuvant in 5 patients (8.2%) and both therapies were performed in 1 
patient (1.6%).  
Median follow-up was of 26.25 months. Twelve complications (17.2%) were 
identified; 3 (4.3%) of which were major complications and 9 (12.85%) minor 
complications. The major complications were reported in 2 cases (2.9%) 
following total mastectomy and in one (1.4%) following nipple-sparing 
mastectomy. Nine minor complications (12.9%) were observed only in 
patients who underwent nipple-sparing mastectomy. No category of 
complication was found to be predominant (Table 2). Regarding the 
association between complications and clinical variables, no significant 
associations at the level of 5% emerged. (Table 3 ). 
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EBR group (201 patients) included 224 reconstructions, of which 158 (70.5%) 
after total mastectomy and 66 (29.5%) after nipple-sparing mastectomy 
(Table1). The median age of patients was 48 years (range, 27-75 years). BMI 
varied from 16 to 37.6 with a median of 23. Considering the factors of 
cardiovascular risk, 6 patients (2.7%) were diabetic, 27 patients (13.4%) were 
hypertensive, 14 patients (7.0%) were smoker and 41 patients (20.4%) had a 
past as a smoker. The volume of the tissue expanders varied from 250 ml to 
800 ml with a median of 500 ml.  
Thirty-eight patients out 201(18.9%) were subjected to radiotherapy. 
Chemotherapy was performed according to adjuvant treatment in 130 
patients (64.7%), according to neoadjuvant treatment in 17 patients (8.5%) 
while both therapies were performed in 12 patients (6.0%).  
Median follow-up time was of 18.82 months. Forty-one complications (18.3%) 
were identified. Twenty-eight (12.5%) were major complications and 13 
(5.8%) were minor (Table 2). Major complications were reported in 19 cases 
(8.5%) following total mastectomy and 9 (4.01%) after nipple-sparing 
mastectomy Five of 13 minor complications (2.23%) were observed in cases 
who underwent nipple-sparing mastectomy. Eight complications (3.57%) 
occurred in cases who underwent total mastectomy Severe infection (4.95%) 
and expander exposure (3.6%) were largely the most frequent categories of 
complication reported (Table 2). Expander explantations were 5 above 11 
major complications in 44 radiated breasts compared to 10 above 17 in 180 
nonirradiated breasts. 
Concerning total complications: in the univariate analysis (Table 3) a 
moderate association with radiotherapy (p = 0.013) and a mild association 
with BMI and expander volume were found. Also, a moderate association was 
found with diabetes (OR=4.7) even though not significant at the level of 5%. 
The variables above were then included in the multivariate model, where,  
only the association with radiotherapy was significant (p<0.05) (Table 4). 
Regarding the outcome of major complications, the univariate analysis 
showed a significant association between complications and implant size 
(p<0.005), BMI (p<0.005), and radiotherapy (p<0.01) (Table 3).  A moderate 
association was found also with  radiotherapy (OR= 3.2, p<0.005) and BMI 
(OR=3.5, p<0.005) So, the variables included in the multivariate analysis 
were the same as those selected in the analysis of total complications. Here, 
moderately significant association of major complications were shown by 
radiotherapy (p<0.05) and BMI  (p<0.05) (Table 4). 
 
Limitations 
These results should be considered with caution considering the small 
sample and confounding bias inherently present in un-randomized analysis. 
The clear difference found between the two groups must be assessed with 
caution considering the associations observed with the other variables. More 
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sophisticated analyses should be required in order to compare these samples 
and correct the potential bias such as propensity score or an analysis of the 
projections of the marginal estimates.  
 
 
DISCUSSION 
 
 
Strengths of our study are the benefit of prospectively collected preoperative 
and operative variables and meticulous collection of postoperative 
complications, which allowed us to control for the described risk factors. Many 
of the earlier studies analyze single risk factor and single complication often 
in a composite group of reconstructive techniques and different types of 
devices. Given the similarity of the surgical techniques which rest on 
muscular or musculo-fascial, fully vascularized, coverage of the device, also 
the types of complications were expected to be homogeneous in the current 
study. Accordingly, the descriptive analysis might suggest a similar 
percentage in the incidence of complications correlated to both surgical 
procedures (DTI: 17.2%; EBR: 18.3%).(Table1) The insertion of a device with 
fixed volume does not jeopardize the safety of the immediate reconstruction 
and there is no evidence that shows more interferences with clinical risk 
factors and adjuvant therapies.  
The complication rate are well comparable with the perioperative complication 
rate of 17.6% reported over a 2-year period in a study from Memorial Sloan-
Kettering Cancer Center (1170 consecutive tissue expander/implant 
reconstructions performed in 884 patients.26 In contrast, Woederman et al. 
described a 39% of 309 patients affected by mild and severe postoperative 
complications after 195 single-stage implant reconstructions and 205 two-
stage reconstructions and suggested the association of the high rate with the 
high number of single-stage reconstructions in patients such as smokers, 
obese patients, and those with larger, more ptotic breasts.27 
 
In this study, even if with the same total number of complications, we have 
interestingly found opposite ratios of minor and major complications, 12.9 vs. 
5.8 (DTI) and 4.3 vs. 12.5 (EBR) respectively. These results that stand for the 
greater safety of the 1-stage surgery must be evaluated with extreme caution 
considering the small sample and confounding bias inherently present in an 
un-randomized analysis. Therefore we decided not to pursue a comparison 
analysis but an analysis of the incidence of complications, in order to study 
their association with different variables.  
 
Age, hypertension and type of mastectomy (total or nipple-sparing) do not 
increase the likelihood for complications in both groups. Smoke slightly 
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increases the rate of major complications exclusively in EBR group, 20% vs. 
10.1% (Odds ratio 2.34; p = 0.05). Diabetes mildly interferes with total 
complications in EBR group (OR 4.69; p = 0.05).  
 
Concerning the main risk factors the results are discussed here. 
 
Radiotherapy 
Univariate analysis in the EBR sample confirms the predictive role of 
radiotherapy in the generation of all complications.28-33. It increases the 
incidence of total complications (p = 0.01; odds ratio 2.6). (Table 8)  This 
evidence is more marked if we consider only the major complications (p < 
0.01; odds ratio 3.2). (Table10) The impact of radiotherapy is similarly found 
in the multivariate analysis.  
 In the subgroup of 44 radiated breasts following EBR the rate of major 
complications (reoperation) is 25%. The overall rate is 31.8%. In DTI the rate 
is lower, 20.0% (1 of 5 radiated breasts), although it is not significant. The 
total reconstructive failure, i.e. the expander removal, occurred in 15 of 41 
overall complications. In particular, the failure rate was 11.36% (5 of 44 
irradiated expanders) vs. 5.55% (10 of 180 nonirradiated expanders).  
In a series of 104 patients with two-stage reconstruction, of whom 27 
underwent radiotherapy before expander exchange (some was radiated 
before salvage mastectomy and expander), Ascherman et al. reported the 
following rates of major complication, i.e. reoperation rates (18.5% for 
irradiated and only 4.2% for nonirradiated breasts, p = 0.025), and of overall 
complication rates (40.7% for irradiated and 16.7% for nonirradiated breasts, 
p 0.01). In addition there were higher rates of implant failure in irradiated 
breasts (14.8 percent versus 0 percent, p = 0.001). The small rates of major 
complication may be explained by the use of a total submuscular coverage.34 
Roostaeian et al.35 significantly found very higher complication rates after 
radiation therapy in expander- or implant-based reconstructions where an 
acellular dermal sling was added to the subpectoral pocket. They reported 
more complications and revisions in the expander group, p < 0.01 
(respectively 5 and 6 of 7 patients treated with radiotherapy), and for revision 
in the implant group, p = 0.05 (4 of 6 radiated patients). 
  
 Cordeiro et al.28 focused the analysis on the expander/implant 
explantation. They reported failure rates before expander exchange mildly 
lower than ours: 8.5% of irradiated vs. 3.6% of nonirradiated breasts). The 
univariate analysis demonstrated that the radiotherapy to the expander group 
had a higher failure rate than the radiotherapy to the permanent implant 
group (18.1 percent versus 12.4 percent), although this difference was not 
significant. Our outcome in DTI group is also encouraging (no implant failure; 
odds of major complications after radiotherapy near 1 likewise with 
nonsignificant p). By contrast, in the current study, the analysis shows 
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significant odds of all major complications after expander radiation (3.33) but 
that are still acceptable in comparison of very high (5.75), found by Cordeiro 
et al., taking into account the limit of a single complication (explantation) but 
after the two stages of surgery for irradiated breasts. Also Sbitany et al.19 
described that the overall early complication rates are higher but acceptable 
compared with nonirradiated patients in two-stage reconstruction even in 
those case with acellular dermal matrix added to the muscular expander 
pocket. 
Other studies showed diverging outcomes of the two-stage 
reconstruction. Nava et al.29 recorded 10 explantations in a group of 50 
irradiated expanders (20%) that became 40% after the exchange with 
permanent implant and compared to 2.3% of nonirradiated group, after a 
median FU of 50 months. On the contrary, Aristei et al.33 found a low rate of 
implant failure, 11.9% after a median FU of 50 months, in 101 patients of 
whom 90 underwent radiation of temporary tissue expanders.  
The study of radiation effects should not limit to one type of complication, 
even if it is the most severe, and the lack of analysis of covariates could 
partially invalidate the outcome of a study. 
 
 
Chemotherapy  
Neoadjuvant and/or adjuvant chemotherapy, primary surgery with or without 
immediate reconstruction, local recurrence control and overall survival are 
strictly related in breast cancer care. Complications after surgery may delay 
and interfere with chemotherapeutic protocols as well as chemotherapeutic 
agents may impair cellular functions necessary for regular recovery from 
surgery and for usual tissue expansion. Nevertheless, we do not record any 
significant higher risk for patients treated with chemotherapy before and after 
surgery. DTI overall complication rates were analogous: 16.7% (36 adjuvant 
treatments) and 14.8% (no treatment). The 33% of complications in DTI 
cases treated by neoadjuvant therapy (odds ratio 2.90) is limited by the few 
cases. Nevertheless, due to the lack of reoperations, recipients of 
neoadjuvant chemotherapy may still be good candidates to DTI. EBR group 
shows higher rate of complications in the 147 cases treated by adjuvant 
chemotherapy (22.4%; odds ratio 2.15) compared to the 11.1% of 18 cases 
treated by neoadjuvant therapy and the 11.1% of 45 cases without 
chemotherapy.  
Peled et al. found no significant difference in a prospective series of patients 
treated by neoadjuvant and adjuvant chemotherapy (expander or implant 
removal rates were 26% vs. 22%  compared to 18% control group).36  
The EBR overall complication odds ratio after neoadjuvant treatment (1.03) is 
comparable with the 0.49 of 30-day postoperative morbidity reported by Abt 
et al. in a large series.37 In a different way, Mitchem et al. prospectively 
observed 32% of expander loss out of 34 patients receiving neoadjuvant 
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chemotherapy but the study lacked information on the complication rate in a 
control group). 38 
Decker et al.39 reported a trend toward increased wound complications in 
patients undergoing mastectomy with immediate reconstruction (odds ratio, 
1.58; p = 0.06). Dorken et al.40 studied short-term complications correlated to 
neoadjuvant therapy and found a rate of 15% in 48 immediate breast 
reconstructions predominantly using permanent implants compared to a 29% 
in the control cases with p = 0.042 (study limitations: age-related differences 
among the groups with p < 0,001; no estimation of adjuvant chemotherapy in 
the control group). 
Our outcome is also comparable to that reported by McCharty et al.26 who 
analyzed all chemotherapeutic treatments as one risk factor without finding 
them to be significantly predictive of complications (12% vs. 16% without 
chemotherapy, OR 0.8, p = 0.26). 
 
 
BMI 
DTI and EBR median values are normal. EBR interquartile range lightly 
includes part of the overweight range (Table 2). Moderate association 
between BMI and increased risk of complications is reported in the study. In 
particular, this is significant in the univariate analysis of the EBR cohort (OR 
4.6, p = 0.0003 for major complications in the preobese patients). Our 
outcome, where the odds for major complications of a patient with BMI = 35 
are seven times greater than that with BMI = 21, is analogous to that found by 
McCharty et al.26 (OR of 6.9 in obese patients compared with nonobese 
patients for reconstructive failure: seven times greater).    
 Other authors as Alderman and Wilkins suggested that BMI and immediate 
reconstruction were correlated with increased complication rates following 
various types of reconstruction.41 
  
  
Device size. 
To the best of our knowledge, expander/implant size has not been previously 
assessed as predictor of surgical complications following implant-based 
breast reconstruction. It is by contrast known that large-volume breasts may 
be significant risk factors for surgical failure. 
The size of the immediate permanent implant is not associated to increasing 
number of complications (OR 1.02). It is valuable for immediate breast 
reconstruction that high-cohesive silicone implants may be safely inserted in 
an uninterrupted musculofascial pocket and without biological sling, within the 
limit of 525 g. According to our single-stage technique, OR using a small size 
(190 g) is the same as using size of 370 or 470 g. 
By contrast in EBR, when the expander volume increases there is a negative 
trend of overall complications (odds radio: 1.2; p <0.05) and, particularly, of 
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major complications (OR 1.2; p <0.005). A patient with a 700cc expander has 
a risk 5.6 times higher than a patient with a 300cc expander. Major volume 
increase, up to 800cc, implies higher incidence of complications and are 
probably associated to the wider dimensions of the pocket and of the skin 
envelope which enhances the production of serum and the risk of bacterial 
contamination. The size impact on major complications might be strictly 
associated to that reported for BMI. The analogous trends of these variables 
can be partly explained by the correlation between body mass and breast 
volume. Generally, a woman with high BMI is supposed to have large breasts 
and possible vascular alterations of the skin associated to a state of 
overweight. 
In univariate analysis of the DTI group there are no significant associations 
between total complications and the considered variables. The effects of the 
expansion may explain the greater impact of the radiotherapy occurred in the 
EBR group. The expansion, in fact, involves a certain amount of tissue 
thinning even if skin viability and capillary blood are not compromised by the 
progressive tissue remodeling. The thinnest layer of expanded skin and 
tissue envelope might have a more negative effect on irradiation boosts.  
Vascular changes are also found in the DTI group because the preserved 
skin envelope is initially subjected to hypoperfusion even when the 
subcutaneous vascular network is still present. Nevertheless, the report of 
minor vascular complications in DTI may be explained with two distinguishing 
factors. The first is given by the fact that an uninterrupted muscolofascial 
layer likely works as a pressure relief so to avoid that skin flaps are subjected 
to the direct pressure of permanent implant of highly cohesive silicone. The 
second factor is given by the graded elongation of muscular fibers in the first 
weeks that facilitates the skin remodeling with retraction instead of the 
delayed expansion occurred in the EBR group. This hypothesis should be 
investigated by biomechanical models in future research. 
 
 
Conclusion 
The expander-based reconstruction is the most popular method of 
immediate reconstruction. In this study there was evidence of significant 
association between complications and clinical variables for the expander 
cohort and not for the implant-based cohort. The association with 
radiotherapy was the most significant in univariate and multivariate analyses, 
less for overweight.  The univariate analysis of major complications showed a 
significant association between complications and implant size, BMI and 
radiotherapy. In particular, we have observed that larger expander volume is 
a significant predictor of failure, especially following radiation. The association 
of very large expander and planned radiation could represent a 
contraindication for the restricted group of overweight patients. The direct-to-
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implant reconstruction of the breast is a safe procedure, without risk of severe 
complications. Non-significant increase is present only for mild complications 
after nipple-sparing mastectomy and after neo-adjuvant therapy. Here we 
have described a method and a safe range of implant size to be used 
overcoming the 500 grams. In the future its grade of surgical safety should be 
better compared to the standard expander-based recontruction in clinical 
trials. In particular this determination is necessary when eterologous or 
alloplastic materials are used in the pocket preparation. 
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Table 1 – Characteristics of reconstructions and patients for the direct to implant (DTI) and the 
expander-based reconstructions (EBR) groups.  
 
 GROUP 
1. Reconstructions DTI (N=70) EBR (N=224) 
Type of Mastectomy: n (%) 
- Total 
- Nac sparing  
 
8 (11.4%) 
62 (88.6%) 
 
158 (70.5%) 
66 (29.5%) 
Complications: n (%)  
 - Total: 
 - Minor 
 - Major 
 
12 (17.2%) 
9 (12.9%) 
3 (  4.3%) 
 
41 (18.3%) 
13 (  5.8%) 
28 (12.5%) 
Volume (ml) :  
    median, range 
    Q1 - Q3 (IQR 
 
370, 125-525 
301-410 (109) 
 
500, 250-800 
350-650 (300)  
2. Patients DTI (N=61) EBR (N=201) 
Age (years) : 
    median, range 
    Q1 - Q3 (IQR) 
 
46,  23-74 
39-50 (11) 
 
48,  27-75 
43-57 (14) 
BMI ( kg / m2 ) : 
    median, range 
    Q1 - Q3 (IQR) 
 
20.6, 16.6-27.8 
19.2-22.9 (3.7) 
 
23.0, 16.0-37.6 
20.7-26.4 (5.7) 
Chemotherapy: n (%) 
 - NO 
 - Adjuvant 
 - Neoadjuvant 
 - Adjuvant +Neoadjuvant 
 
24 (39.3%) 
31 (50.9%) 
5 (  8.2%) 
1 (  1.6%) 
 
42 (20.9%) 
130 (64.7%) 
17 (  8.5%) 
12 (  6.0%) 
Radiotherapy: n (%) 
- NO 
- YES 
 
57 (93.4%) 
4 (  6.6%) 
 
163 (81.1%) 
38 (18.9%) 
Hypertension: n (%) 
- NO 
- YES 
 
57 (93.4%) 
4 (6.6%) 
 
174 (86.6%) 
27 (13.4%) 
Diabetes: n (%) 
- NO 
- YES 
 
61 (100%) 
0 ( 0.0%) 
 
195 (97.0%) 
6 (  3.0%) 
 Smoke: n (%) 
 - NO 
 - YES 
 - EX 
- not available 
 
47 (77.0%) 
2 (  3.3%) 
12 (19.7%) 
 
 
127 (63.1%) 
14 (  7.0%) 
41 (20.4%) 
19 (  9.5%) 
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Table 2 – details about major and minor complications 
GROUP: DTI (N=70) GROUP: EBR (N=224) 
1. MINOR COMPLICATIONS: n (%) 
- Poor aesthetic result 
- Implant displacement  
- Phlogosis 
- Seroma  
- Rippling on the medial quadrants due to thinned  tissue 
- Breast pain, alteration of the scapular and humeral movement 
- Skin necrosis with fistula formation 
 
 
TOTAL 
 
2   ( 2.9%) 
1   ( 1.4%)   
2   ( 2.9%) 
1   ( 1.4%)  
1   ( 1.4%) 
1   ( 1.4%) 
1   ( 1.4%) 
 
 
9  (12.9%) 
1. MINOR COMPLICATIONS: n (%) 
- Infections 
- Seroma 
- Wound deishence 
- Stretched skin and scar tension 
- Pain in axillary and dorsal region  
- Necrosis 
- Phlogosis 
- Hematoma 
- Lateralization of  tissue expander 
TOTAL  
 
3 (  1.3%)  
1 (  0.4%) 
1 (  0.4%) 
2 (  0.9%) 
1 (  0.4%) 
1 (  0.4%) 
2 (  0.9%) 
1 (  0.4%) 
1 (  0.4%) 
13 (  5.8%) 
2. MAJOR COMPLICATIONS: n (%) 
- Poor aesthetic result 
- Implant rotation with hypercorrection of the upper quadrants Baker 2/3 
- NMR showed  a  microcracking of the right implant 
 
 
 
TOTAL  
 
1  ( 1.4%) 
 
1  ( 1.4%) 
1  ( 1.4%) 
 
 
 
3  ( 4.3%) 
2. MAJOR COMPLICATIONS: n (%) 
- Infections 
- Phlogosis 
- Exposure of tissue expander 
- Breakage / damage of tissue expander 
- Recurrent seroma  
- Skin necrosis 
- Lateralization of  tissue expander 
TOTAL 
 
11 (  4.9%) 
 3  (  1.3%) 
8  (  3.6%) 
3  (  1.3%)  
1  (  0.4%) 
1  (  0.4%) 
1  (  0.4%)  
28 (12.5%) 
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Table 3 – association between complications and patient and reconstruction characteristics: univariate analyses Reported in the table are: frequencies of 
complications (n) and overall reconstructions (N) (categorical variables only); estimated odds ratios of complication with respective 95% C.I.s; p-value from association tests. For 
chemotherapy, p-values were reported only for the test of overall association. Since in each case the overall association was not significant, comparisons between groups were nor 
performed. OR = odds ratio, p = p-value, NR = not reported, ref = reference category for the calculation of Odds Ratios 
1 in the DTI group only one patient with both adjuvant and neoadjuvant therapy was present: thus, was excluded. * p<0.05 
 
 
DTI: total complications:  EBR: total complications  EBR: major complications:  
frequencies: 
n/N (%) 
Estimates: 
OR (95% C.I.) ; p 
frequencies: 
n/N (%) 
Estimates: 
OR (95% C.I.) ; p 
frequencies: 
n/N (%) 
Estimates: 
OR (95% C.I.) ; p 
Type of mastectomy: 
- total 
- nac sparing 
 
2/8 (25.0%) 
10/62 (16.1%) 
 
ref  
0.52 (0.11,   3.13) ; 0.440 
 
28/158 (17.7%) 
13/66 (19.7%) 
 
ref 
       1.16 (0.55, 2.34) ; 0.70 
 
20/158 (12.7%) 
8/66 (12.1%) 
 
ref 
0.98 (0.40, 2.25) ; 0.966 
Chemotherapy:  
- NO 
- Adjuvant 
- Neoadjuvant 
- Adj  + Neoadj 
 
 
- NO 
- YES 
 
4/27 (14.8%) 
6/36 (16.7%) 
2/6 (33.3%) 
 
 
 
4/27 (14.8%) 
8/42 (19.0%) 
 
ref 
1.11 (0.30,   4.44) ; -  
2.90 (0.41, 18.54) ; - 
 
overall association: p= 0.526 
 
ref 
1.29 (0.38, 4.91) ; 0.692 
 
5/45 (11.1%) 
33/147 (22.4%) 
2/18 (11.1%) 
1/14 (  7.1%) 
 
 
5/45 (11.1%) 
36/179 (20.1%)  
 
ref 
2.15 (0.87, 6.30) ; - 
1.12 (0.19, 5.19) ; - 
0.82 (0.08, 4.64) ; - 
overall association: p= 0.236 
 
ref 
1.87 (0.77, 5.44) ; 0.177 
 
3/45 (  6.6%) 
23/147 (15.6%) 
1/18 (  5.5%) 
1/14 (  7.1%) 
 
 
3/45 (  6.7%) 
25/179 (14.0%) 
 
ref 
2.29 (0.79,   8.90) ; - 
1.04 (0.10,   6.89) ; - 
1.35 (0.12,   9.10) ; - 
overall association: p= 0.391 
 
ref 
2.00 (0.70, 7.74) ; 0.211 
Radiotherapy:  
- NO 
- YES 
 
11/65 (16.9%) 
1/5 (20.0%) 
 
ref 
1.58 (0.15, 9.67) ; 0.657 
 
27/180 (15.0%) 
14/44 (31.8%) 
 
ref 
2.65 (1.24, 5.56) ; 0.013 *  
 
17/180 (  9.4%) 
11/44 (25.0%) 
 
ref 
3.21 (1.37, 7.32) ; 0.0080 *  
Diabetes:  
- NO 
 
0/65 (0%) 
- 
 
38/218 (17.4%) 
 
ref 
 
26/218 (11.9%) 
 
ref 
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- YES  3/6 (50.0%) 4.69 (0.96, 22.90) : 0.056 2/6 (33.3%) 4.04 (0.68, 19.21) ; 0.115 
Hypertension:  
- NO 
- YES 
 
11/66 (16.7%) 
1/4 (25.0%) 
 
ref 
2.07 (0.19, 14.08) ; 0.499 
 
35/194 (18.0%) 
6/30 (20.0%) 
 
ref 
      1.19 (0.43, 2.91) ; 0.717 
 
25/194 (12.9%) 
3/30 (10.0%) 
 
ref 
   0.85 (0.22, 2.49) ; 0.779 
Smoke: n (%) 
- NO 
- YES or EX 
 
9/54 (16.7%) 
3/16 (18.8%) 
 
ref 
0.96 (0.17, 3.98) ; 0.956 
 
21/139 (15.1%)  
16/65 (24.6%) 
 
ref 
      1.84 (0.88, 3.78) ; 0.102 
 
14/139 (10.1%) 
13/65 (20.0%) 
 
ref 
   2.23 (0.98, 5.02) ;   0.054 
Age  1.01 (0.95, 1.07) ; 0.734        1.03 (0.995, 1.06) ;0.097     1.02 (0.99, 1.06) ;     0.243   
Overweight (BMI≥25)  
- NO 
- YES 
 
11/63 (17.5%) 
1/7 (14.3%) 
 
ref 
1.05 (0.10, 5.77) ; 0.957 
 
20/141 (14.2%) 
21/83 (25.3%) 
 
ref 
2.04 (1.03, 4.04) 0.040 * 
 
10/141 (  7.1%) 
18/83 (21.7%) 
 
ref 
3.54 (1.59, 8.23) 0.0018 * 
Volume  0.99 (0.54, 1.89) ; 0.983  1.25 (1.0051, 1.55) ; 0.045 *  1.44 (1.12, 1.88) ; 0.0045 * 
 
 
 
TABLE 4 – association between complications and patient and reconstruction characteristics: multivariate analyses 
OR = Estimated odds ratios of complication with respective 95% C.I.s. * p<0.05 
 
 
EBR: total complications: EBR: major complications  
 Estimates: 
OR (95% C.I.) 
p-value 
 
Estimates: 
OR (95% C.I.) 
p-value: 
 
Radiotherapy 2.46 (1.13,  5.24)  0.0235 * 2.95 (1.23,  6.94)  0.0165 * 
Age 1.01 (0.98,  1.05) 0.4026 1.01 (0.97,  1.04) 0.7918 
Overweight 1.51 (0.68,  3.34) 0.3079 2.56 (1.02,  6.59) 0.0445 * 
Volume 1.11 (0.86,  1.42) 0.4477 1.20 (0.90,  1.61) 0.2222 
Diabetes 2.90 (0.54,15.56) 0.2046 1.93 (0.29,10.45) 0.4663 
 
 
